Arizona Respiratory Center, University of Arizona, Tucson, AZ, USA; Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; IMIM (Hospital del Mar Research Institute), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Respir Med. 2013 Dec;107(12):1923-30. doi: 10.1016/j.rmed.2013.07.013. Epub 2013 Aug 3.
YKL-40 is a chitinase-like protein that, in cross-sectional clinical studies, has been associated with severe asthma and COPD in smokers.
To determine the longitudinal relation of circulating YKL-40 to levels and decline of lung function in the general population.
We used longitudinal data from up to 13 surveys from the population-based TESAOD study which was conducted in Tucson, Arizona between 1972 and 1996. In cross-sectional analyses, we also used data from 3 Spanish centers of the multicenter ECRHS study (ECRHS-Sp). Serum YKL-40 was measured at baseline in TESAOD and in survey 2 in ECRHS-Sp using ELISAs. Multivariate linear regression was used to test associations of serum YKL-40 to concomitant lung function. In TESAOD, random coefficients models were used to test associations of serum YKL-40 to subsequent decline of lung function.
Data on YKL-40 and lung function were available from 1088 TESAOD and 854 ECRHS-Sp adult participants (59% and 51% females; respectively). In adjusted multivariate meta-analyses, being in the highest YKL-40 quartile was associated cross-sectionally with significant deficits in FEV1 and FVC %predicted. In adjusted longitudinal analyses, TESAOD participants in the top YKL-40 quartile had an FEV1 decline that was 5 ml/yr (p = 0.05) faster than subjects in the third quartile, 5 ml/yr (p = 0.02) faster than subjects in the second quartile, and 10 ml/yr (p < 0.001) faster than subjects in the lowest YKL-40 quartile. These longitudinal effects were particularly strong in smokers and absent in never smokers. After adjusting for covariates, as compared with the other three quartiles combined, the top YKL-40 quartile was associated with a 9 ml/yr (p = 0.001) faster FEV1 decline among smokers, while no significant effects were found among never smokers (2 ml/yr, p = 0.35).
Circulating YKL-40 is associated with levels and decline of lung function in the general population and may be a biomarker of susceptibility to the long-term effects of cigarette smoking.
YKL-40 是一种几丁质酶样蛋白,在横断面临床研究中,它与吸烟者的严重哮喘和 COPD 有关。
确定循环 YKL-40 与一般人群肺功能水平和下降的纵向关系。
我们使用了基于人群的 TESAOD 研究中多达 13 次调查的纵向数据,该研究于 1972 年至 1996 年在亚利桑那州图森市进行。在横断面分析中,我们还使用了多中心 ECRHS 研究(ECRHS-Sp)的 3 个西班牙中心的数据。在 TESAOD 中,使用 ELISA 在基线和 ECRHS-Sp 的第 2 次调查中测量血清 YKL-40。多元线性回归用于测试血清 YKL-40 与同时的肺功能之间的关联。在 TESAOD 中,随机系数模型用于测试血清 YKL-40 与随后肺功能下降的关联。
来自 1088 名 TESAOD 和 854 名 ECRHS-Sp 成年参与者(分别为 59%和 51%的女性)的 YKL-40 和肺功能数据可用。在调整后的多元荟萃分析中,处于 YKL-40 最高四分位数的个体与 FEV1 和 FVC %predicted 的显著缺陷相关。在调整后的纵向分析中,TESAOD 参与者中处于 YKL-40 最高四分位数的个体的 FEV1 下降速度比第三四分位数快 5ml/yr(p=0.05),比第二四分位数快 5ml/yr(p=0.02),比最低 YKL-40 四分位数快 10ml/yr(p<0.001)。这些纵向影响在吸烟者中尤为明显,而在从不吸烟者中则不存在。调整协变量后,与其他三个四分位数组合相比,YKL-40 最高四分位数与吸烟者中 FEV1 下降速度快 9ml/yr(p=0.001)相关,而从不吸烟者中则无明显影响(2ml/yr,p=0.35)。
循环 YKL-40 与一般人群的肺功能水平和下降有关,可能是对吸烟长期影响易感性的生物标志物。